Sun Pharmaceutical’s consolidated net profit fell 36% to ₹1,989 crore for July to September. Revenue from operations rose 12% to ₹16,199 crore.
US formulation sales fell 8.2% to $455 million. India sales rose 17.3% to ₹5,552 crore, and global innovative medicines grew 6.9% to $356 million. The EBITDA margin narrowed to 29.3% from 31.3%. The company did not give a reason for the drop in profit.